

**ASX Announcement**

**7 October 2024**

## **OncoSil Medical Limited Signs Distribution Agreement with Al Zahrawi Medical Supplies LLC for the GCC Region**

**Sydney, Australia – 7 October 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce it has signed an exclusive distribution agreement with Al Zahrawi Medical Supplies LLC, a premier medical device distributor based in Dubai, United Arab Emirates. The agreement grants Al Zahrawi Medical Supplies exclusive rights to market and distribute OncoSil™ across the Gulf Cooperation Council (GCC) countries, which include the United Arab Emirates (UAE), Qatar, Oman, and Bahrain.

The OncoSil™ device is an innovative brachytherapy solution that is implanted directly into a patient’s pancreatic tumor, delivering targeted radiation to improve treatment outcomes. This technology has been CE marked and is undergoing broader adoption across several regions globally. With the signing of this agreement, we continue to expand our footprint into new international markets, helping patients gain access to advanced cancer care.

**Nigel Lange, CEO & Managing Director of OncoSil Medical, commented:**

"We are thrilled to partner with Al Zahrawi Medical Supplies, a highly respected distributor with a proven track record across the GCC region. This agreement marks an important step in expanding access to our innovative OncoSil™ product in the Middle East, where there is a growing demand for effective treatments for pancreatic cancer. Al Zahrawi’s expertise and established network will be invaluable in helping to bring our technology to patients in these key markets."

**Mr. Abdulrahman Ramadan, Group CEO of Zahrawi Group, added:**

"We are thrilled to partner with OncoSil Medical to introduce their pioneering OncoSil™ technology to the GCC region. This strategic alliance is particularly vital as pancreatic cancer continues to impact more lives in our communities. By combining our extensive market knowledge and distribution capabilities, we aim to deliver innovative and effective treatment options that address this urgent need. Our commitment to improving patient outcomes drives us to ensure that cutting-edge solutions like OncoSil™ are accessible to those who need them most. Together, we aspire to make a meaningful difference in the lives of patients and their families throughout the region."

### **About Zahrawi Group:**

Established in 1989, Zahrawi Group is a pioneer Medical Devices and Life Science Distributor in the Gulf region, with a presence in UAE, KSA, Qatar, Oman, and Bahrain. Zahrawi Group is specialized in Surgical,



Medical, Nuclear Medicine, Diagnostic, and Analytical Lab solutions, and was founded with a vision to be the leading and most trusted partner in the GCC.

Zahrawi Group is committed to improving people's lives by introducing innovative Healthcare products, Smart solutions, and Outstanding services.

To learn more, visit [zahrawigroup.com](http://zahrawigroup.com) and connect on [X\(Twitter\)](#), [LinkedIn](#), [Facebook](#), [Instagram](#), and [YouTube](#).

### Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

### For further information, please contact:

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--	--	---

### About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>